FcγR Immune Complex ELISA Reducing Background Noise
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immune complex ELISAs face challenges with standardization of RF IgM, high background reactions due to excess monomeric IgG, and require long incubation times, which affect sensitivity and reproducibility.
Innovation Solution
Using FcγR, particularly CD32, to bind and quantify immune complexes, allowing for improved sensitivity and reproducibility by immobilizing it on a solid phase and incubating with both antibodies and antigens simultaneously, thereby reducing background noise and shortening assay time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If RF IgM is used to bind immune complexes in traditional IC ELISA, then immune complexes can be detected, but standardization is difficult and background reactions increase due to excess monomeric IgG
Solution Approach 1:
The patent introduces FcγR as an intermediary binding protein that specifically recognizes the Fc region of IgG antibodies in immune complexes. This mediator selectively binds ICs while excluding excess monomeric IgG, thereby reducing background reactions and improving measurement precision without requiring standardization of patient-derived RF IgM.
Solution Approach 2:
The patent extracts and utilizes the FcγR binding domain that specifically recognizes the Fc region of IgG. By isolating this specific binding capability and using it as the solid phase coating, the method separates the desired IC binding function from the problematic non-specific binding of monomeric IgG that occurs with RF IgM.
2Measurement precision
If traditional IC ELISA methods are used with RF IgM, then immune complexes can be detected, but long incubation times are required which reduces assay efficiency
Solution Approach 1:
The patent changes the binding parameter by using FcγR with high affinity and specificity for the Fc region of IgG. This parameter change in binding characteristics enables faster association kinetics and more efficient immune complex capture, reducing the incubation time required while maintaining or improving detection sensitivity.
3Measurement precision
If FcγR is used to bind immune complexes, then detection specificity improves, but new standardization challenges arise with FcγR preparation
Solution Approach 1:
The patent employs FcγR as a stable, well-characterized protein that can be produced recombinantly in large quantities with consistent quality. This approach replaces the need for standardization of patient-derived RF IgM with a manufacturable protein that has defined binding characteristics, simplifying the standardization process while maintaining high detection specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the specificity and sensitivity of immune complex detection, reduces background noise, and improves assay efficiency by allowing for high dilutions of reagents, making it suitable for high-throughput testing and better standardization compared to traditional methods.
Implementation Method 1
FcγR (such as CD16, CD32 or CD64) bind to the Fc region of IgG and can thus be used for the in vitro quantification of antibodies in the form of immune complexes
Implementation Method 2
The quantity of label detected correlates with the quantity of antibody in immune complexed form. The enzyme may be peroxidase, e.g., horseradish peroxidase
Data Source
AI summary
The present invention relates to the field of diagnostic or analytic methods. In particular, the inventors teach that FcγR such as CD16, CD32 or CD64 may be used for in vitro quantification of antibodies in the form of immune complexes, i.e., complexes formed by antigen and specific antibody. A method for detection and quantification of antibodies in the form of immune complexes is also provided.